OncoMatch/Clinical Trials/NCT06765161
Efgartigimod in IVIG Dependent Myasthenia Gravis Patients
Is NCT06765161 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies efgartigimod administration for myasthaenia gravis.
Treatment: efgartigimod administration — This study is an open label, single center, prospective, 26 weeks study with descriptive analysis where IVIG is replaced by efgartigimod therapy. MG-ADL and MGQOL evaluations will occur weekly throughout the study to week 26.
Check if I qualifyExtracted eligibility criteria
Prior therapy
Must have received: intravenous immunoglobulin — chronic regular treatment for myasthenia gravis for the past year or more
Receiving chronic regular IVIG treatments for myasthenia gravis for the past year or more
Cannot have received: anti-CD20 antibody (rituxan)
previous rituxan or eculizumab treatment or plasma exchange within the past six months
Cannot have received: C5 complement inhibitor (eculizumab)
previous rituxan or eculizumab treatment or plasma exchange within the past six months
Cannot have received: plasma exchange
previous rituxan or eculizumab treatment or plasma exchange within the past six months
Cannot have received: surgery
previous thymectomy within the past 3months
Lab requirements
Kidney function
egfr >= 30 ml/min
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify